Patents by Inventor Michael McDevitt

Michael McDevitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220356266
    Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.
    Type: Application
    Filed: April 16, 2021
    Publication date: November 10, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Adam ZWOLAK, Jason HO, Natasa OBERMAJER, Michael DIEM, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Theresa MCDEVITT, Fei SHEN
  • Publication number: 20210145988
    Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 20, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Sarah M. CHEAL, Michael MCDEVITT, Ouathek OUERFELLI, Steven M. LARSON, Guangbin YANG
  • Patent number: 8540965
    Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: September 24, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jón Njardarson, Mark Reid Philips
  • Publication number: 20090304581
    Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.
    Type: Application
    Filed: July 31, 2006
    Publication date: December 10, 2009
    Inventors: David A. Scheinberg, Michael McDevitt, Debjit Chattopadhyay, Mark Reid Philips
  • Patent number: 6683162
    Abstract: The present invention provides functionalized chelants and a method of treating cancerous cells with alpha particles comprising the step of administering a pharmacologically effective dose of an 225Ac conjugate comprising a functionalized chelant R is independently CHQCO2X; Q is independently hydrogen; C1-C4 alkyl or (C1-C2 alkyl) phenyl; X is independently hydrogen; benzyl or C1-C4 alkyl; Z1 is (CH2)nY where n is 1-10 and Y is an electrophilic or nucleophilic moiety and Z2 is R; or, alternatively, Z1 is hydrogen and Z2 is a peptide linker composed of 1-10 amino acids; said Y or said peptide linker covalently attached to an antibody or fragment thereof, or other biologic molecule; or a pharmaceutically acceptable salt thereof, complexed with 225Ac. These biologic molecule binds to cancerous cells and 225Ac or its daughters emit alpha particles into said cancerous cells effecting treatment.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: January 27, 2004
    Assignee: Sloan Kettering Institute of Cancer Research
    Inventors: David Scheinberg, Dangshe Ma, Michael McDevitt, Paul Borchardt
  • Publication number: 20030228258
    Abstract: The present invention provides a cytotoxic MHC I conjugate comprising a cytotoxic moiety, biotinylated MHC I monomers which each comprise an antigenic peptide and streptavidin, bound to the cytotoxic moiety or to a biotinylated cytotoxic moiety and to the biotinylated MHC I monomers. Alternative constructs comprising a cytotoxic moiety and biotinylated MHC I monomers where each monomer comprises an antibody fragment also are provided. The cytotoxic moiety may comprise an 225Ac radionuclide or other cytotoxin. Further provided are methods of killing CD8+T cell clonal populations.
    Type: Application
    Filed: May 30, 2003
    Publication date: December 11, 2003
    Inventors: David Scheinberg, Michael McDevitt, Rui-Rong Yuan
  • Publication number: 20020058007
    Abstract: The present invention provides functionalized chelants and a method of treating cancerous cells with alpha particles comprising the step of administering a pharmacologically effective dose of an 225Ac conjugate comprising a functionalized chelant 1
    Type: Application
    Filed: September 14, 2001
    Publication date: May 16, 2002
    Inventors: David Scheinberg, Michael McDevitt, Paul Borchardt, Dangshe Ma
  • Patent number: 6266295
    Abstract: A system and method provide an event display. The event display includes a visual indication of a day on which the event occurs. The event display also includes an analog clock face representation having a contrasting portion indicating a time of the event.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: July 24, 2001
    Assignee: Microsoft Corporation
    Inventors: Kathryn L. Parker, Michael McDevitt, Greg Keyser, Scott A. Skorupa